8-K: Travere Therapeutics Soars on Strong Q3 FILSPARI Sales

Travere Therapeutics reported robust third-quarter 2025 financial results, driven by significant FILSPARI sales growth and strategic financial achievements, including debt retirement and a key milestone payment.

Summary

• U.S. net product sales for FILSPARI grew 155% year-over-year to $90.9 million in the third quarter of 2025.
• Total revenue for the third quarter of 2025 reached $164.9 million, including a $40.0 million market-access milestone from CSL Vifor and $9.3 million of non-cash license revenue.
• The company achieved a net income of $25.7 million, or $0.29 per basic share, for Q3 2025, a significant improvement from a net loss of $54.8 million in Q3 2024.
• Approximately $68.9 million of principal and accrued interest on the remaining 2025 convertible notes were repaid, strengthening the financial foundation.
• The U.S. FDA approved a REMS modification for FILSPARI in August 2025, removing the embryo-fetal toxicity monitoring requirement and reducing liver monitoring frequency to every three months.
• Updated 2025 KDIGO guidelines now include FILSPARI for earlier, first-line use in IgAN patients at risk of progression.
• The supplemental New Drug Application (sNDA) for FILSPARI in FSGS remains under FDA review with a PDUFA target action date of January 13, 2026, and the FDA has informed the company that an advisory committee is no longer needed.
• Progress is being made toward restarting the pivotal HARMONY Study of pegtibatinase in 2026.
• Renalys Pharma, Inc., a partner, expects topline results from its registrational Phase 3 clinical trial of sparsentan for IgAN in Japan in the fourth quarter of 2025.
• Renalys Pharma, Inc. entered into an agreement to be acquired by Chugai Pharmaceutical Co., Ltd., granting Chugai exclusive rights to develop and commercialize sparsentan in Japan, South Korea, and Taiwan, with the transaction expected to close in Q4 2025.

Sentiment

Score: 8

Explanation: The company reported exceptionally strong financial results, including significant revenue growth and a shift to net profitability. Strategic financial moves, positive regulatory updates for key products, and pipeline advancements indicate robust operational momentum and a promising future outlook.

Positives

• U.S. net product sales of FILSPARI demonstrated exceptional growth, increasing 155% year-over-year to $90.9 million in Q3 2025.
• Total revenue for Q3 2025 was $164.9 million, a substantial increase from $62.9 million in Q3 2024, reflecting strong commercial execution and milestone recognition.
• The company transitioned from a net loss of $54.8 million in Q3 2024 to a net income of $25.7 million in Q3 2025, indicating improved profitability.
• Successfully retired the remaining $68.9 million of 2025 convertible notes, significantly strengthening the balance sheet.
• Achieved and received a $40.0 million market access milestone payment from CSL Vifor, further bolstering financial resources.
• The FDA approved a favorable REMS modification for FILSPARI, simplifying monitoring requirements for prescribers and patients.
• FILSPARI's inclusion in the 2025 KDIGO guidelines for earlier, first-line use in IgAN reinforces its position as a foundational therapy.
• The FDA's decision to no longer require an advisory committee for the FSGS sNDA could streamline the approval process for FILSPARI in FSGS.
• Meaningful progress is being made towards restarting the pivotal HARMONY Study of pegtibatinase, advancing the pipeline.
• The acquisition of partner Renalys Pharma by Chugai Pharmaceutical expands sparsentan's commercial reach and potential in key Asian markets.

Negatives

• Selling, general, and administrative (SG&A) expenses increased significantly to $86.5 million in Q3 2025 from $65.6 million in Q3 2024, primarily due to preparations for the potential FSGS launch and increased IgAN commercialization investment.
• Total other income, net, decreased to $0.8 million in Q3 2025 from $1.3 million in Q3 2024, mainly attributable to lower interest income.

Risks

• Uncertainties exist regarding the timing and outcome of the sNDA review for FILSPARI in FSGS, with no guarantee of FDA approval on the anticipated timeline or at all.
• The success of commercial products, including FILSPARI, depends on market acceptance, efficacy, safety, price, reimbursement, and benefit over competing therapies.
• Risks are associated with the challenges of manufacturing scale-up for commercial products.
• Ongoing or planned clinical trials, such as the HARMONY Study for pegtibatinase, may not succeed or could be delayed for safety, regulatory, or other reasons.
• The company faces risks related to its dependence on contractors for clinical drug supply and commercial manufacturing.
• Uncertainties exist regarding patent protection, exclusivity periods, and intellectual property rights of third parties.
• Risks are associated with regulatory interactions and potential changes in regulatory landscape.
• Competitive products, including current and potential future generic competition, and technological changes may limit demand for the company's products.
• Global and macroeconomic conditions, including health epidemics and pandemics, could disrupt clinical trials, commercialization activity, supply chain, and manufacturing operations.

Future Outlook

The company is well-positioned for a potential FDA approval and commercial launch of FILSPARI for FSGS in the first quarter of 2026, actively preparing for this event. Management anticipates supporting long-term growth and is making meaningful progress toward restarting the pivotal HARMONY Study of pegtibatinase in 2026. Additionally, partner Renalys Pharma expects topline results from its IgAN Phase 3 trial in Japan in Q4 2025, and its acquisition by Chugai Pharmaceutical is expected to close in the same quarter, expanding sparsentan's global reach.

Management Comments

• "We delivered outstanding commercial performance in the third quarter, reflecting the growing role of FILSPARI as a foundational therapy in IgAN. This success underscores the strength of our commercial execution and the expanding confidence in FILSPARI among physicians and patients."
• "We continue to be pleased with the progress of our sNDA review in FSGS and are actively preparing for a potential FDA approval early next year."
• "We are also making meaningful progress toward restarting the pivotal HARMONY Study of pegtibatinase and have positioned the company to support long-term growth."
• "We are entering the final months of 2025 in a position of strength as we remain focused on execution and on expanding our impact for people living with rare disease."

Industry Context

FILSPARI's inclusion in the updated KDIGO guidelines for IgAN as a first-line, nephroprotective therapy significantly strengthens its market position and clinical validation within the nephrology community. The potential FDA approval of FILSPARI for FSGS would establish it as the first and only approved medicine for this rare kidney disease, addressing a critical unmet need. The acquisition of Renalys Pharma by Chugai Pharmaceutical underscores the global pharmaceutical industry's interest in rare kidney disease treatments and expands the commercial footprint for sparsentan in key Asian markets, reflecting a broader trend of strategic partnerships and M&A in the rare disease space.

Comparison to Industry Standards

• FILSPARI is highlighted as the only therapy with proven efficacy compared to optimized Renin-Angiotensin System inhibitors (RASi) in clinical trials, with more patients enrolled in the PROTECT study than in all prior RASi trials combined, setting a high benchmark for treatment efficacy in IgAN.
• If approved, FILSPARI would be the first and only FDA-approved medicine for Focal Segmental Glomerulosclerosis (FSGS), positioning it as a market leader in this specific rare kidney disease segment, where no comparable approved therapies currently exist.

Corporate Governance

Stakeholder Impact

• Shareholders are likely to benefit from the strong financial performance, significant revenue growth, return to profitability, and strategic debt reduction, which could positively influence share price and investor confidence.
• Patients with IgAN and potential future patients with FSGS will benefit from improved access to FILSPARI due to simplified monitoring requirements and the potential for a new FDA-approved treatment option.
• Physicians treating IgAN will find FILSPARI's inclusion in KDIGO guidelines and simplified REMS make it a more attractive and easier-to-prescribe foundational therapy.
• Employees may experience increased job security and potential growth opportunities due to the company's strong performance, pipeline advancements, and strategic positioning for long-term growth.
• Partners like CSL Vifor and Renalys Pharma (and soon Chugai) benefit from successful collaborations and strategic transactions that expand market access and development opportunities for sparsentan.

Next Steps

• Prepare for potential FDA approval and commercial launch of FILSPARI for FSGS in 1Q 2026.
• Restart enrollment in the Phase 3 HARMONY Study of pegtibatinase in 2026.
• Renalys Pharma, Inc. expects topline results from its registrational Phase 3 clinical trial of sparsentan for IgAN in Japan in Q4 2025.
• The acquisition of Renalys Pharma, Inc. by Chugai Pharmaceutical Co., Ltd. is expected to close in Q4 2025.
• Present new data from SPARTAN, real-world data on FILSPARI, and analyses from PROTECT and DUPLEX studies at ASN Kidney Week 2025 (November 6-9).

Key Dates

Recommendation

The company delivered exceptional Q3 2025 results, marked by a 155% year-over-year growth in FILSPARI sales, a significant turnaround to net profitability, and strategic debt reduction. Positive regulatory developments, including a favorable REMS modification and the FDA's decision to forgo an advisory committee for the FSGS sNDA, de-risk key pipeline assets and enhance market potential. The ongoing progress with pegtibatinase and the strategic acquisition of its partner Renalys Pharma by Chugai further solidify its global market presence and long-term growth prospects. These factors collectively indicate strong operational momentum and a highly favorable outlook, making it a compelling investment opportunity.

Keywords

Travere Therapeutics, TVTX, FILSPARI, sparsentan, IgAN, FSGS, IgA Nephropathy, Focal Segmental Glomerulosclerosis, rare disease, nephrology, kidney disease, pegtibatinase, HARMONY Study, CSL Vifor, Renalys Pharma, Chugai, FDA approval, PDUFA, Q3 2025 financial results, biopharmaceutical, clinical trials, commercial launch